CDKL5 Deficiency Disorder (CDD) is a rare developmental epileptic encephalopathy (DEE) caused by mutations in the CDKL5 gene.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Insights
- The total CDKL5 Deficiency Disorder prevalent population in 7MM in 2017 was 16,397
- The total CDKL5 Deficiency Disorder diagnosed prevalence in the United States in 2017 –
- 208 – males
- 1,315 – females
- Mainly eight types of clinical characteristics of CDD are observed in patients in 2017 :-
- 1,234 – Epileptic Spasms
- 716 – Hypsarrhythmia
- 1,142 – Cortical Visual Impairment
- 1,218 – Hand Stereotypies
- 1,317 – Gastrointestinal Symptoms
- 1,080 – Constipation
- 976 – Reflux
- 1,295 – Sleep Difficulties
CDKL5 Deficiency Disorder Market Insight
CDKL5 Deficiency Disorder market size in 7MM in 2017 was USD 5.95 Million
CDKL5 Deficiency Disorder Market Drivers
- Understanding molecular biology of CDKL5 Deficiency Disorder (CDD)
- Increased Awareness
- Therapeutic Opportunities
- Upsurge in Research and Development
- Research beyond clinical trials
CDKL5 Deficiency Disorder Market Barriers
- Treatment Resistant Seizures
- Fewer Patients
- Fewer Clinical Trials
Scope of the Report
- The report covers the descriptive overview of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market
1. Key Insights
2. Executive Summary of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder
3. Competitive Intelligence Analysis for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder
4. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Market Overview at a Glance
4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Share (%) Distribution in 2017
4.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Share (%) Distribution in 2030
5. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment and Management
8.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Seven Major Market Analysis
13.1. Key Findings
13.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size in 7MM
13.3. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in the United States
15.1.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in Germany
15.3.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in France
15.4.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in Italy
15.5.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in Spain
15.6.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in the United Kingdom
15.7.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Total Market Size in Japan
15.8.3. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/